eMJA: Articles on Pharmacology

eMJA The Medical Journal of Australia

Articles on Pharmacology

245 articles

Hepatic encephalopathy precipitated by sodium valproate therapy [Letters] H S Subhash, Robert J Heddle, David W Schultz, John Ring and Campbell H Thompson Med J Aust 2008; 188 (9): 549.
Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study [Research] Niklaus Kamber, Wendy A Davis, David G Bruce and Timothy M E Davis Med J Aust 2008; 188 (8): 446-449.
Unplanned admissions to two Sydney public hospitals after naltrexone implants [Research] Nicholas Lintzeris, Soung Lee, Lucinda Scopelliti, James Mabbutt and Paul S Haber Med J Aust 2008; 188 (8): 441-444.
Ensuring the safety of new medications and devices: are naltrexone implants safe? [Editorials] Alex D Wodak, Robert Ali, David Henry and Lloyd Sansom Med J Aust 2008; 188 (8): 438-439.
Prolonged absorption and delayed peak paracetamol concentration following poisoning with extended-release formulation [Notable Cases] Darren M Roberts and Nicholas A Buckley Med J Aust 2008; 188 (5): 310-311.
Learning from error: identifying contributory causes of medication errors in an Australian hospital [Research] Pamela Nichols, Tandy-Sue Copeland, Ian A Craib, Paul Hopkins and David G Bruce Med J Aust 2008; 188 (5): 276-279.
Persistence with antihypertensive medication: Australia-wide experience, 2004–2006 [Health Care] Leon A Simons, Michael Ortiz and Gordon Calcino Med J Aust 2008; 188 (4): 224-227.
In the long run, skills are as good as pills for attention deficit hyperactivity disorder [Editorials] Joseph M Rey Med J Aust 2008; 188 (3): 133-134.
A national survey on knowledge and perceptions of senior medical students in Australia about generic medicines [Letters] Mohamed Azmi Ahmad Hassali, Kay Stewart and David C M Kong Med J Aust 2008; 188 (2): 123-124.
Why do interns make prescribing errors? A qualitative study [Health Care] Ian D Coombes, Danielle A Stowasser, Judith A Coombes and Charles Mitchell Med J Aust 2008; 188 (2): 89-94.
MIMS is not a stand-alone resource [Letters] James L Mallows || David T Graham Med J Aust 2007; 187 (10): 596-597.
MIMS is not a stand-alone resource [Letters] James L Mallows || David T Graham Med J Aust 2007; 187 (10): 596-597.
Guidelines for the management of acute coronary syndromes 2006 [Letters] Mark Little and Chris Johnstone || Constantine N Aroney and Philip Aylward, for the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand Med J Aust 2007; 187 (6): 372.
Management of warfarin in atrial fibrillation [Letters] Peter W Ford and Angela Close || Beata V Bajorek Med J Aust 2007; 187 (6): 371.
Mis-deca-n identity? [Letters] Elizabeth A S Giugni, Rachel S Boddy and Natalie G Limet Med J Aust 2007; 187 (6): 370.
Paralysis caused by “nagging” [Notable Cases] Michaela Cartner, Michael Sinnott and Peter Silburn Med J Aust 2007; 187 (6): 366-367.
Serotonin toxicity: a practical approach to diagnosis and treatment [Clinical Update] Geoffrey K Isbister, Nicholas A Buckley and Ian M Whyte Med J Aust 2007; 187 (6): 361-365.
Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease [Letters] Beatrice A Golomb and Marcella A Evans Med J Aust 2007; 187 (4): 253-253.
Reference pricing for pharmaceuticals: is the Australia–United States Free Trade Agreement affecting Australia&rsq [Viewpoint] Thomas A Faunce Med J Aust 2007; 187 (4): 240-242.
Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme [For Debate] Andrew Searles, Susannah Jefferys, Evan Doran and David A Henry Med J Aust 2007; 187 (4): 236-239.
The National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007: reform or fracture? [Editorials] Ken J Harvey, Anthony H Harris and Liliana Bulfone Med J Aust 2007; 187 (4): 206-207.
Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression? [Letters] David P Horgan || Murray J Walters, Alston M Unwin and Sean B Gills || Nicholas A Keks, Graham D Burrows, David L Copolov, Richard Newton, Nick Paoletti, Isaac Schweitzer and John W G Tiller Med J Aust 2007; 187 (3): 198-200.
Ototoxic ear drops with grommet and tympanic membrane perforations: a position statement [Letters] Robert J Black, Vince C Cousins, Peter Chapman, Zoran Becvarovski, Harvey L C Coates, Stephen J O’Leary, Christopher F Perry and Brian J Williams Med J Aust 2007; 187 (1): 62.
Evaluating medicines: let’s use all the evidence [Letters] Mira L Harrison-Woolrych Med J Aust 2007; 186 (12): 662.
Ototoxic ear drops with grommet and tympanic membrane perforations: a position statement [Letters] Robert J Black, Vince C Cousins, Peter Chapman, Zoran Becvarovski, Harvey L C Coates, Stephen J O’Leary, Christopher F Perry and Brian J Williams Med J Aust 2007; 186 (11): 605-606.
Medicines and breastfeeding: information is available on safe use [Matters Arising] Lisa H Amir Med J Aust 2007; 186 (9): 485.
The National Prescribing Service should lead [Matters Arising] Jim R Stockigt Med J Aust 2007; 186 (9): 484.
Call in independent information sources [Matters Arising] John S Dowden Med J Aust 2007; 186 (9): 484.
MIMS is not a stand-alone resource [Matters Arising] Elizabeth A Donohoo Med J Aust 2007; 186 (9): 484.
Misleading information for consumers [Matters Arising] David Torpy Med J Aust 2007; 186 (9): 483-484.
Deficiencies in drug interaction information [Matters Arising] Michelle Sweidan and James F Reeve Med J Aust 2007; 186 (9): 483.
Specialist societies can assist [Matters Arising] Leon A Bach Med J Aust 2007; 186 (9): 483.
Reporting units for therapeutic drug monitoring: a correctable source of potential clinical error [Viewpoint] Graham R D Jones Med J Aust 2007; 186 (8): 420-421.
Off-label use of medicines: consensus recommendations for evaluating appropriateness [Letters] Allen C Cheng, Priscilla M Robinson and Ken Harvey Med J Aust 2007; 186 (7): 379-380.
Evaluating medicines: let’s use all the evidence [Viewpoint] Chris W Kelman, Sallie-Anne Pearson, Richard O Day, C D'Arcy J Holman, Erich V Kliewer and David A Henry Med J Aust 2007; 186 (5): 249-252.
Australia needs a better system for health care evaluation [Editorials] Fiona J Stanley and Eric M Meslin Med J Aust 2007; 186 (5): 220-221.
The "therapeutic footprint" of medical, complementary and alternative therapies and a doctor's duty of care [Letters] Craig S Hassed, Vicki Kotsirilos, Marie Pirotta and Avni Sali || Christine R Sanderson, Bogda Koczwara and David C Currow Med J Aust 2007; 186 (4): 214-215.
Convulsions associated with an overdose of St John’s wort [Letters] Dharshi C Karalapillai and Rinaldo Bellomo Med J Aust 2007; 186 (4): 213-214.
An unusual cause of severe metabolic acidosis [Letters] Mark A Boyd and Stephen Hedger || John V Peter, Natasha Rogers and Sandra L Peake Med J Aust 2007; 186 (3): 158-159.
Ten years of highly active antiretroviral therapy for HIV infection [New Drugs, Old Drugs] Luke F Chen, Jennifer Hoy and Sharon R Lewin Med J Aust 2007; 186 (3): 146-151.
Stimulant prescribing for the treatment of ADHD in Western Australia: socioeconomic and remoteness differences [Research] Janine Calver, David Preen, Max Bulsara and Frank Sanfilippo Med J Aust 2007; 186 (3): 124-127.
Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? [Letters] Lauren J Bailey and Vasi Naganathan || Henry Krum Med J Aust 2007; 186 (2): 99-101.
Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease [Notable cases] Tim Walker, Joe McCaffery and Chris Steinfort Med J Aust 2007; 186 (2): 91-94.
Barriers in the quest for quality drug information: salutary lessons from TGA-approved sources for thyroid-related medic [Review] Jim R Stockigt Med J Aust 2007; 186 (2): 76-79.
Product information past perfect [Editorials] John S Dowden Med J Aust 2007; 186 (2): 51-52.
XmasTM (brand substitution not permitted) [Christmas Offerings] Jonathan Bromley and Nicholas A Buckley Med J Aust 2006; 185 (11/12): 687.
Doctors behaving badly? [Matters Arising] Martin H N Tattersall and Ian H Kerridge Med J Aust 2006; 185 (11/12): 674-675.
Misleading title [Matters Arising] Padraic J Grattan-Smith Med J Aust 2006; 185 (11/12): 674.
Disclosure needs to include the extent of a relationship [Matters Arising] Charles M Fisher Med J Aust 2006; 185 (11/12): 673.
Don't regulate - abolish [Matters Arising] Hans Peter Dietz Med J Aust 2006; 185 (11/12): 673.
Drug company sponsored symposia fulfil an important educational role [Matters Arising] Ian S Collins Med J Aust 2006; 185 (11/12): 673.
Off-label use of medicines: consensus recommendations for evaluating appropriateness [Health Care] Madlen Gazarian, Maria Kelly, John R McPhee, Linda V Graudins, Robyn L Ward and Terence J Campbell Med J Aust 2006; 185 (10): 544-548.
Clinical trials of unapproved medicines in Australia [Letters] Jonathon Rankin, Jenny Mason, Neil Kottege and Natasha Y Andersson Med J Aust 2006; 185 (6): 342-343.
Early medical abortion in Australia: more common than statistics suggest? [Letters] Caroline M de Costa Med J Aust 2006; 185 (6): 341.
Epidemic Clostridium difficile [Editorials] Thomas V Riley Med J Aust 2006; 185 (3): 133-134.
Adverse drug events: counting is not enough, action is needed [Letters] Graeme C Miller, Helena C Britt, Lisa Valenti and Stephanie Knox Med J Aust 2006; 184 (12): 646.
Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes [Notable Cases] Geoffrey K Isbister, Lindsay Murray, Sally John, L Peter Hackett, Tedo Haider, Phebe O'Mullane, Sophie Gosselin and Frank Daly Med J Aust 2006; 184 (7): 354-356.
Adverse drug events: counting is not enough, action is needed [Editorials] Elizabeth E Roughead and Joel Lexchin Med J Aust 2006; 184 (7): 315-316.
Pharmaceutical Benefits Scheme limitations on macrolides: implications for pertussis management [Letters] Kari A J Jarvinen, Bradley J McCall, Clare B Nourse, Joe G McCormack and Martyn H Tilse Med J Aust 2006; 184 (6): 309.
Cefotetan-induced life-threatening haemolysis [Letters] Heather E Robinson, Ellen L Maxwell, H Miles Prince, MaryA O'Reilly and Andrew Jakobovits Med J Aust 2006; 184 (5): 251.
The prevention, detection, and management of breast cancer [Clinical Update] Nehmat Houssami, Jack Cuzick and J Michael Dixon Med J Aust 2006; 184 (5): 230-234.
The use of therapeutic medications for soft-tissue injuries in sports medicine [Letters] C Scott Masters and Michael J Yelland || Justin A Paoloni and John W Orchard Med J Aust 2006; 184 (4): 198-199.
Microscopic colitis associated with exposure to lansoprazole [Lessons from Practice] Sarah N Hilmer, Timothy R Heap, Robert P Eckstein, Christopher S Lauer and Gillian M Shenfield Med J Aust 2006; 184 (4): 185-186.
4. The use and misuse of performance-enhancing substances in sport [MJA Practice Essentials — Sports M] John W Orchard, Peter A Fricker, Susan L White, Louise M Burke and Deborah J Healey Med J Aust 2006; 184 (3): 132-136.
Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis [Clinical Update] Lynden J Roberts, Leslie G Cleland, Ranjeny Thomas and Susanna M Proudman Med J Aust 2006; 184 (3): 122-125.
Use of prescribed medications in a South Australian community sample [Letters] Rohan A Elliott || Robert D Goldney and Laura J Fisher Med J Aust 2006; 184 (2): 96.
Pethidine in emergency departments: promoting evidence-based prescribing [Letters] Biswadev Mitra and Peter Cameron || Paul Pielage || Karen I Kaye, Susan A Welch, Linda V Graudins, Andis Graudins, Tai Rotem, Sharon R Davis and Richard O Day Med J Aust 2006; 184 (1): 44-45.
Chronic kidney disease and automatic reporting of estimated glomerular filtration rate [Matters Arising] Terry E Jones Med J Aust 2006; 184 (1): 42.
Improving the availability of artesunate for treatment of severe malaria [Editorials] Nicholas M Anstey, Ric N Price and Nicholas J White Med J Aust 2006; 184 (1): 3-4.
Where there’s smoke, there’s Mucomyst? [Letters] Jim Siderov Med J Aust 2005; 183 (11/12): 655.
1. The use of therapeutic medications for soft-tissue injuries in sports medicine [MJA Practice Essentials — Sports M] Justin A Paoloni and John W Orchard Med J Aust 2005; 183 (7): 384-388.
Depressed youth, suicidality and antidepressants [Letters] Robert D Goldney || Peter R Mansfield, Melissa K Raven and Jon N Jureidini || Joseph M Rey and Michael J Dudley || Duncan J Topliss Med J Aust 2005; 183 (5): 275-276.
Use of prescribed medications in a South Australian community sample [Medicine and the Community] Robert D Goldney and Laura J Fisher Med J Aust 2005; 183 (5): 251-253.
Spontaneous bruising, haematomata and prolonged APTT with meloxicam [Letters] Anil M Kurien Med J Aust 2005; 183 (4): 219.
Pharmaceutical advertisements in prescribing software: an analysis [Marketing — Research] Ken J Harvey, Agnes I Vitry, Elizabeth Roughead, Rosalie Aroni, Nicola Ballenden and Ralph Faggotter Med J Aust 2005; 183 (2): 75-79.
Is the pharmacology of corticosteroids in the lung modified by age? [Management — Asthma Supplement] J Paul Seale Med J Aust 2005; 183 (1 Suppl): S47-S48.
The aromatase inhibitors in early breast cancer: who, when, and why? [Clinical Update] Ilona C Nordman, Andrew J Spillane and Anne L Hamilton Med J Aust 2005; 183 (1): 24-27.
Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safe [Research] Terrence H Diamond, Kenneth W Ho, Peter G Rohl and Matthew Meerkin Med J Aust 2005; 183 (1): 10-12.
Weight gain and diabetes with “second-generation” antipsychotic drugs [Letters] Andrew Firestone Med J Aust 2005; 182 (12): 652-653.
Should thyroxine tablets be refrigerated? Have we got it wrong in Australia? [Letters] Jim R Stockigt || Ovais Siddiqui Med J Aust 2005; 182 (12): 650.
A community-based intervention to reduce antibiotic use for upper respiratory tract infections in regional South Austra [Medicine and the Community] William B Dollman, Vanessa T LeBlanc, Lynette Stevens, Peter J O’Connor and John D Turnidge Med J Aust 2005; 182 (12): 617-620.
Tailoring access to high cost, genetically targeted drugs [Editorials] Wayne D Hall, Robyn Ward, Winston S Liauw, Jo-anne E Brien and Christine Y Lu Med J Aust 2005; 182 (12): 607-608.
Tramadol and seizures [Letters] Ian W Boyd Med J Aust 2005; 182 (11): 595-596.
Bisphosphonates and osteonecrosis of the jaw [ADRAC Report] Patrick M Purcell and Ian W Boyd Med J Aust 2005; 182 (8): 417-418.
Bisphosphonates and avascular necrosis of the jaw: a possible association [Notable cases] Glen Carter, Alastair N Goss and Chris Doecke Med J Aust 2005; 182 (8): 413-415.
Access to medicines and high-quality therapeutics: global responsibilities for clinical pharmacology [Conference report] Richard O Day, Donald J Birkett, John Miners, Gillian M Shenfield, David A Henry and J Paul Seale Med J Aust 2005; 182 (7): 322-323.
Correction [Correction] Maria Hannah Pia de Guzman, Sureka Thiagalingam, Poh Yan Ong and Ivan Goldberg Med J Aust 2005; 182 (6): 312.
Barriers to diagnosing and managing heart failure in primary care [Letters] Alexandra A Bennett, Jo-anne E Brien and Peter S Macdonald Med J Aust 2005; 182 (6): 309.
Lipid-modifying drugs [New Drugs, Old Drugs] Leon A Simons and David R Sullivan Med J Aust 2005; 182 (6): 286-289.
Adverse drug reactions in older Australians, 1981–2002 [Research] Christel L Burgess, C D’Arcy J Holman and Anthony G Satti Med J Aust 2005; 182 (6): 267-270.
Managing adverse drug reactions: time to get serious [Editorials] Elizabeth E Roughead Med J Aust 2005; 182 (6): 264-265.
COX-2 inhibitors: exemplars of the drug-safety conundrum [Editorials] Mark R Nelson, Andrew M Tonkin, Flavia M Cicuttini and John J McNeil Med J Aust 2005; 182 (6): 262-263.
The direct thrombin inhibitor melagatran/ximelagatran [Letters] Luke R Bereznicki, Shane L Jackson and Gregory M Peterson Med J Aust 2005; 182 (5):254-255.
Inhalation-device polypharmacy in asthma [Letters] Vanessa M McDonald and Peter G Gibson Med J Aust 2005; 182 (5):250-251.
Acute interstitial nephritis secondary to esomeprazole [Lessons from practice] Nimeshan Geevasinga, Lukas Kairaitis, Gopala K Rangan and Patrick L Coleman Med J Aust 2005; 182 (5):235-236.
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions [Matters Arising] Paul Langton, Graeme Hankey and John Eikelboom Med J Aust 2005; 182 (4):199.
Paracetamol should be first-line therapy in osteoarthritis [Matters Arising] Richard O Day and Garry G Graham Med J Aust 2005; 182 (4):198-199.
Possible genetic predisposition to cardiac effects [Matters Arising] Hari Manev and Radmila M Manev Med J Aust 2005; 182 (4):198.
COX-2 selectivity varies across class [Matters Arising] Leslie G Cleland and Michael J James Med J Aust 2005; 182 (4):197-198.
Withdraw all COX-2-selective drugs [Matters Arising] Peter R Mansfield, Agnés I Vitry and James M Wright Med J Aust 2005; 182 (4):197.
Artemisinin-based combination therapies for uncomplicated malaria [New Drugs, Old Drugs] Timothy M E Davis, Harin A Karunajeewa and Kenneth F Ilett Med J Aust 2005; 182 (4):181-185.
Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in East Timor [Public Health] Scott J Kitchener, Peter E Nasveld, Robin M Gregory and Michael D Edstein Med J Aust 2005; 182 (4):168-171.
Bilateral acute angle closure caused by supraciliary effusions associated with venlafaxine intake [Lessons from practice] Maria Hannah Pia de Guzman, Sureka Thiagalingam, Poh Yan Ong and Ivan Goldberg Med J Aust 2005; 182 (3):121-123.
Myasthenia gravis and a rare complication of chemotherapy [Notable cases] Christina V T Ng Med J Aust 2005; 182 (3):120.
A case of desquamating rash associated with methadone use [Notable cases] Natalie Kordjian, Annabelle D Donaldson, Dedee F Murrell and Steven A Krilis Med J Aust 2005; 182 (2): 76-77.
A syndromic rash in patients attending methadone clinics in New South Wales [Notable cases] Jon N Currie, Lucinda Wallman, Jimmy Chien, Lisa Snell, Margaret Cluff, Karen Scrivener and Elizabeth M Benson Med J Aust 2005; 182 (2): 73-75.
Correction: Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Haemostasis and Thrombosis [Correction] Ross I Baker, Paul B Coughlin, Alex S Gallus, Paul L Harper, Hatem H Salem and Erica M Wood Med J Aust 2005; 182 (1): 48.
Subsidised access to TNF-α inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defens [Letters] Erica L Mann Med J Aust 2005; 182 (1): 47-48.
Audit of prescribed nicotine replacement therapy to hospital inpatients who smoke [Letters] Barbara A Hawkshaw and Yeqin Zuo Med J Aust 2005; 182 (1): 43-44.
Tramadol and new-onset seizures [Letters] Angelo Labate, Mark R Newton, Graeme M Vernon and Samuel F Berkovic Med J Aust 2005; 182 (1): 42-43.
Drugs, sport and the Olympics 2000-2004 [Letters] Anthony P Millar Med J Aust 2004; 181 (10): 584.
Critical shortage of injectable thiamine in Australia [Letters] Simon Spedding and Matt D Gaughwin Med J Aust 2004; 181 (10): 577-578.
The dearth of new antibiotic development: why we should be worried and what we can do about it [For Debate] Patrick G P Charles and M Lindsay Grayson Med J Aust 2004; 181 (10): 549-553.
Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital [Research] Zanariah Hussein, John M Wentworth, Alison J Nankervis, Joseph Proietto and Peter G Colman Med J Aust 2004; 181 (10): 536-539.
Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis [Position Statement] Ross I Baker, Paul B Coughlin, Alex S Gallus, Paul L Harper, Hatem H Salem and Erica M Wood; the Warfarin Reversal Consensus Group Med J Aust 2004; 181 (9): 492-497.
Preventing intrathecal administration of vincristine [Letters] Peter J Gilbar and Christine V Carrington Med J Aust 2004; 181 (8): 464.
Subsidised access to TNFα inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensi [Letters] Christine Y Lu, Kenneth M Williams, Lyn March, James V Bertouch and Richard O Day || Lloyd N Sansom Med J Aust 2004; 181 (8): 457-458.
The direct thrombin inhibitor melagatran/ximelagatran [New Drugs, Old Drugs] Timothy A Brighton Med J Aust 2004; 181 (8): 432-437.
Trends and regional differences in testosterone prescribing in Australia, 1991–2001 [Research] David J Handelsman Med J Aust 2004; 181 (8): 419-422.
Testosterone prescribing in Australia [Editorials] Bronwyn GA Stuckey Med J Aust 2004; 181 (8): 412-413.
Drugs, sport and the Olympics 2000–2004 [Letters] Michael C S ennedy Med J Aust 2004; 181 (4): 227.
The other side of the coin: safety of complementary and alternative medicine [Complementary and Alternative Medicine] Stephen P Myers and Phillip A Cheras Med J Aust 2004; 181 (4): 222-225.
Major advances in bipolar disorder [Clinical Update] Philip B Mitchell, Gin S Malhi and Jillian R Ball Med J Aust 2004; 181 (4): 207-210.
Ciprofloxacin in the treatment of chronic suppurative otitis media [Letters] James D Kidd Med J Aust 2004; 181 (2): 84.
Good medicine and bad medicine: science to promote the convergence of “alternative” and orthodox medicine [Complementary and Alternative Medicine] John M Dwyer Med J Aust 2004; 180 (12): 647-648.
The beginning of the end of warfarin? [Editorial] John W Eikelboom and Graeme J Hankey Med J Aust 2004; 180 (11): 549-551.
Impact of an electronic antibiotic advice and approval system on antibiotic prescribing in an Australian teaching hospi [Healthcare] M Lindsay Grayson, Sharmila Melvani, Sue W Kirsa, Stephen Cheung, Anthony M Korman, M Kent Garrett and William A Thomson Med J Aust 2004; 180 (9): 455-458.
Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners [Letters] Timothy HJ Florin || Stephen J Kerr, Andrea Mant, Fiona E Horn, Kevin McGeechan and Geoffrey P Sayer || John S Dowden Med J Aust 2004; 180 (6): 310-312.
Licensing thalidomide in Australia [Letters] Colin L Crawford || Martin H N Tattersall Med J Aust 2004; 180 (4): 199-200.
Effect of computerised prescribing on use of antibiotics [Letters] Ian D Coombes, Danielle A Stowasser, Charles A Mitchell and Paul Varghese Med J Aust 2004; 180 (3): 140-141.
Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners [Letters] Mark R Nelson Med J Aust 2004; 180 (3): 140.
Long-acting sulfonylureas — long-acting hypoglycaemia [ Lessons from Practice ] Peter C Veitch and Rory J Clifton-Bligh Med J Aust 2004; 180 (2) : 84-85.
Metformin and serious adverse effects [ Editorials ] Janelle C Nisbet, Joanna M Sturtevant and Johannes B Prins Med J Aust 2004; 180 (2) : 53-54.
Dosing information for paediatric patients: are they really “therapeutic orphans”? [Letters] Amanda J Caswell Med J Aust 2003; 179 (10): 560.
The PBS community awareness campaign: how helpful is blaming patients? [Viewpoint] Evan Doran and David A Henry Med J Aust 2003; 179 (10): 544-545.
Mirtazapine-induced hyponatraemia [Letters] Milton G Roxanas Med J Aust 2003; 179 (8): 453-454.
Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners [Research] Stephen J Kerr, Andrea Mant, Fiona E Horn, Kevin McGeechan and Geoffrey P Sayer Med J Aust 2003; 179 (8): 403-407.
Coax, COX and cola [Editorials] John S Dowden Med J Aust 2003; 179 (8): 397-398.
The effect of recalling paracetamol on hospital admissions for poisoning [Letters] Corrine M Balit, Geoffrey K Isbister, Andrew H Dawson, Frank F Daly and Ian M Whyte Med J Aust 2003; 179 (4): 221-223.
Dosing information for paediatric patients: are they really “therapeutic orphans”? [Healthcare] Elaine Tan, Noel E Cranswick, Craig R Rayner and Colin B Chapman Med J Aust 2003; 179 (4): 195-198.
A simple intervention to improve hospital antibiotic prescribing [Letters] Jill S Butty Med J Aust 2003; 179 (3): 175-176.
Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin [Letters] Sam LS Yuen and Bruce McGarity Med J Aust 2003; 179 (3): 172.
Aspirin for cardiovascular disease prevention [Position Statement] Joseph Hung, for the Medical Issues Committee of the National Heart Foundation of Australia Med J Aust 2003; 179 (3): 147-152.
Indomethacin and long-term outcome for tiny babies [EBM: Trials on Trial] Lex W Doyle Med J Aust 2003; 179 (2): 103-104.
Long-term management of venous thromboembolism: is there a role for low-intensity warfarin therapy? [Editorials] John W Eikelboom and Graeme J Hankey Med J Aust 2003; 179 (2): 68-69.
Effect of computerised prescribing on use of antibiotics [Letters] F Frank Pyefinch Med J Aust 2003; 179 (1): 62-63.
Eardrop attacks: seizures triggered by ciprofloxacin eardrops [Lessons from Practice] Carolyn F Orr and Dominic B Rowe Med J Aust 2003; 178 (7): 343.
Antiplatelet drugs [New Drugs, Old Drugs] Graeme J Hankey and John W Eikelboom Med J Aust 2003; 178 (11): 568-574.
Managing patients with "treatment-resistant" schizophrenia [Schizophrenia] Christos Pantelis and Timothy J R Lambert Med J Aust 2003; 178 (9 Suppl): S62-S66.
Pharmacological approaches to the management of schizophrenia [Schizophrenia] Timothy J R Lambert and David J Castle Med J Aust 2003; 178 (9) Suppl 5 May: S57-S61.
Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use? [Editorials] Bart J Currie and Alan R Clough Med J Aust 2003; 178 (9): 421-422.
In reply: Low-molecular-weight heparins and heparinoids [Letters] John W Eikelboom and Graeme J Hankey Med J Aust 2003; 178 (8): 414-415.
Low-molecular-weight heparins and heparinoids [Letters] Owen D Williamson and Alison M. Street Med J Aust 2003; 178 (8): 414.
Low-molecular-weight heparins and heparinoids [Letters] Barry NJ Walters and Dorothy Graham Med J Aust 2003; 178 (8): 413-414.
Thalidomide and cancer? [Letters] J Mark Elwood Med J Aust 2003; 178 (8): 413.
Magnesium infusion to treat Irukandji syndrome [Letters] Michael A Corkeron Med J Aust 2003; 178 (8): 411.
Impact of a web-based antimicrobial approval system on broad-spectrum cephalosporin use at a teaching hospital [Research] Michael J Richards, Marion B Robertson, Jonathan G A Dartnell, Margarida M Duarte, Nicholas R Jones, Dale A Kerr, Lyn-Li Lim, Peter D Ritchie, Graham J Stanton and Simone E Taylor Med J Aust 2003; 178 (8): 386-390.
The verdict from ALLHAT [Letters] Mark R Nelson Med J Aust 2003; 178 (6): 304.
A Quality Use of Medicines program for continuity of care in therapeutics from hospital to community [Letters] Joseph J Gelb Med J Aust 2003; 178 (6): 299-300.
In reply: A Quality Use of Medicines program for continuity of care in therapeutics from hospital to community [Letters] Karen I Kaye, Andrea Mant, Linda Kehoe and Wendy C Rotem Med J Aust 2003; 178 (6): 299-300.
Inhaled steroids — too much of a good thing? [Letters] Dianne P Goeman, Susan M Sawyer, Michael J Abramson, Kay Stewart, Francis C K Thien, Rosalie A Aroni and Jo A Douglass Med J Aust 2003; 178 (5): 247.
In reply: Ventricular tachycardia following ingestion of a commonly used antihistamine [Letters] Dennis L Kuchar, Bruce D Walker and Charles W Thorburn Med J Aust 2003; 178 (5): 246.
Ventricular tachycardia following ingestion of a commonly used antihistamine [Letters] Philip T Sager and Enrico P Veltri Med J Aust 2003; 178 (5): 245-246.
Adrenal crises in children treated with high-dose inhaled corticosteroids for asthma [Notable Cases] Joseph S Macdessi, Tabitha L Randell, Kim C Donaghue, Geoffrey R Ambler, Peter P van Asperen and Craig M Mellis Med J Aust 2003; 178 (5): 214-216.
Effect of computerised prescribing on use of antibiotics [Research] David A Newby, Jayne L Fryer and David A Henry Med J Aust 2003; 178 (5): 210-213.
A simple intervention to improve hospital antibiotic prescribing [Research] Michael South, Jenny Royle and Michael Starr Med J Aust 2003; 178 (5): 207-209.
Doctors' perceptions and attitudes to prescribing within the Authority Prescribing System [Research] Siaw-Teng Liaw, Christopher M Pearce, Patty Chondros, Barry P McGrath, Leone Piggford and Kay Jones Med J Aust 2003; 178 (5): 203-206.
Good prescribing: where to next? [Editorials] Robert F W Moulds Med J Aust 2003; 178 (5): 196-197.
In reply: Epidemiological modelling (including economic modelling) and its role in preventive drug therapy [Letters] Danny Liew, John J McNeil, Anna Peeters, Stephen S Lim and Theo Vos Med J Aust 2003; 178 (4): 188-189.
Fatal envenomation by jellyfish causing Irukandji syndrome [Letters] Andrew H Dawson Med J Aust 2003; 178 (3): 139.
The effect of recalling paracetamol on hospital admissions for poisoning in Western Australia [Medicine and the Community] Stephen R Kisely, David Lawrence and Neil J Preston Med J Aust 2003; 178 (2): 72-74.
Bupropion poisoning: a case series [Research] Corrine R Balit, Christa N Lynch and Geoffrey K Isbister Med J Aust 2003; 178 (2) 61-63.
Withdrawal of methylphenobarbitone [Letters] Mervyn J Eadie Med J Aust 2003; 178 (1): 44.
Epidemiological modelling (including economic modelling) and its role in preventive drug therapy [Letters] Kent R Johnson and Marissa N Lassere Med J Aust 2002; 178 (4): 188-189.
In reply: The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors [Letters] John P Edmonds, Richard O Day and James V Bertouch Med J Aust 2002; 177 (10): 573-573.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors [Letters] Madlen Gazarian and Karen I Kaye Med J Aust 2002; 177 (10): 572-573.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors [Letters] Agnes I Vitry and Eve Hurley Med J Aust 2002; 177 (10): 572-573.
Licit psychostimulant consumption in Australia, 1984–2000: international and jurisdictional comparison [Research] Constantine G Berbatis, V Bruce Sunderland and Max Bulsara Med J Aust 2002; 177 (10): 539-543.
Thiazolidinediones and type 2 diabetes: new drugs for an old disease [Correction] Trisha M O'Moore-Sullivan and Johannes B Prins Med J Aust 2002; 177 (7): 396.
Linezolid-induced neuropathy [Letters] Carmela E Corallo and Amalie E Paull Med J Aust 2002; 177 (6): 332-332.
11: Antibiotic resistance [MJA Practice Essentials — Infectio] Peter J Collignon Med J Aust 2002; 177 (6): 325-329.
Is dexamethasone effective in treating acute migraine headache? [EBM in action] Jason Wasiak and Jeremy N Anderson Med J Aust 2002; 176 (2002): 83.
Hyponatraemia and hypokalaemia caused by indapamide [Letters] Laurence G Howes Med J Aust 2002; 176 (12): 53-54.
Paracetamol recall: a natural experiment influencing analgesic poisoning [Letters] David Gunnell Med J Aust 2002; 176 (11): 561-563.
Perhexiline toxicity related to citalopram use [Letters] Karin Nyfort-Hansen Med J Aust 2002; 176 (11): 560-561.
Ceftriaxone and cefotaxime use in Victorian hospitals [Research] Marion B Robertson, Tony M Korman, Jonathan G A Dartnell, Lisa L Ioannides-Demos, Sue W Kirsa, Julie A V Lord, Liliana Munafo, Graham B Byrnes and on behalf of the Victorian Drug Usage Evaluation Group Med J Aust 2002; 176 (11): 524-529.
Antibiotic guidelines: improved implementation is the challenge [Editorials] D Ashley R Watson Med J Aust 2002; 176 (11): 513-514.
The pharmacotherapy of smoking cessation [New Drugs, Old Drugs] Matthew J Peters and Lucy C Morgan Med J Aust 2002; 176 (10): 486-490.
Ventricular tachycardia following ingestion of a commonly used antihistamine [Notable Cases] Dennis L Kuchar, Bruce D Walker and Charles W Thorburn Med J Aust 2002; 176 (9): 429-430.
"Order effect" in the provision of medication information [Letter to the Edito] Abilio C de Almeida Neto, Timothy F Chen and Joyce H L Chan Med J Aust 2002; 176 (8): 401-402.
Thiazolidinediones and type 2 diabetes: new drugs for an old disease [New Drugs, Old Drugs] Trisha M O'Moore-Sullivan and Johannes B Prins Med J Aust 2002; 176 (8): 381-386.
Thiazolidinediones and type 2 diabetes: new drugs for an old disease [New Drugs, Old Drugs] Trisha M O'Moore-Sullivan and Johannes B Prins Med J Aust 2002; 176 (8): 381-386.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors [Evidence-based Medicine] John P Edmonds, Richard O Day and James V Bertouch Med J Aust 2002; 176 (7): 332-334.
Considerations for the safe prescribing and use of COX-2-specific inhibitors [ Position Statement ] The Australian COX-2-Specific Inhibitor (CSI) Prescribing Group* Med J Aust 2002; 176 (7) : 328-331.
Pharmacological treatment of cognitive deficits in Alzheimer's disease [Letters] William Lam Med J Aust 2002; 176 (6): 297.
Overview of drug use [Book Review] Jane Robertson Med J Aust 2002; 176 (6): 276 .
Megadose vitamin C in treatment of the common cold: a randomised controlled trial [Letters] Luis Vitetta, Avni Sali, Bill Paspaliaris and Nicola J Reavley Med J Aust 2002; 176 (5): 298-299.
Mirtazapine-induced akathisia [Letters] Boregowda G Girishchandra, Liana Johnson, Rebecca M Cresp and Kenneth G D Orr Med J Aust 2002; 176 (5): 242.
Venlafaxine and bilateral acute angle closure glaucoma [Letters] Bradley Ng, G Mark C Sanbrook, Anthony J Malouf and Smita A Agarwal Med J Aust 2002; 176 (5): 241.
Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine [Letters] Felicity H Prior, Geoffrey K Isbister, Andrew H Dawson and Ian M Whyte Med J Aust 2002; 176 (5): 240-241.
Hyponatraemia and hypokalaemia due to indapamide [Healthcare] Michael D Chapman, Ross Hanrahan, John McEwen and John E Marley Med J Aust 2002; 176 (5): 219-221.
Paracetamol recall: a natural experiment influencing analgesic poisoning [Medicine and the Community] Corrine R Balit, Geoffrey K Isbister, Jennifer Peat, Andrew H Dawson and Ian M Whyte Med J Aust 2002; 176 (4): 162-165.
Content of isoflavone- containing preparations [Letters] Jan B Howes and Laurence G Howes Med J Aust 2002; 176 (3): 135-136.
COX-2 inhibition and [Letters] Christopher G Fenn Med J Aust 2002; 176 (2): 88.
Neurology and neurosurgery [Medicine] Graeme J Hankey Med J Aust 2002; 176 (1): 26.
Gastroenterology and hepatology [Medicine] Amanda J Nicoll, Ian J Kronborg and Neville D Yeomans Med J Aust 2002; 176 (1): 14.
Clinical pharmacology [Medicine] Gillian M Shenfield , David G Le Couteur and Laurent P Rivory Med J Aust 2002; 176 (1): 9.
Medical research into "neglected diseases" (In reply) [Letter] Alan H Evans Med J Aust 2001; 175: 668-669
Medical research into "neglected diseases" [Letter] Mary K Moran, Catherine M Hewison, Rowan D Gillies Med J Aust 2001; 175: 667-668
Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin [Notable Cases] Peter B Ward, Paul D R Johnson, Elizabeth A Grabsch, Barrie C Mayall and M Lindsay Grayson Med J Aust 2001; 175: 480-483
Anticoagulation in pregnancy and the puerperium [Position Statement] A Working Group on behalf of the Obstetric Medicine Group of Australasia Med J Aust 2001; 175: 258-263
Risk of death from methicillin-resistant Staphylococcusaureus bacteraemia: a meta-analysis [Systematic Review] Michael Whitby, Mary-Louise McLaws and Geoffrey Berry Med J Aust 2001; 175 (5): 264-267.
Bupropion-induced hypersensitivity reactions [ADRAC] Elizabeth Benson Med J Aust 2001; 174: 650-651
Poisoning with the recreational drug paramethoxyamphetamine ( [Healthcare] Liang Han Ling, Colin Marchant, Nicholas A Buckley, Michael Prior and Rod J Irvine Med J Aust 2001; 174: 453-455
Would the pharmaceutical companies please mind their Ps and Qs, and their Xs, Ys and Zs [Christmas Offerings] Gordon B Parker Med J Aust 2000; 173: 662-663
Recent trends in the use of antidepressant drugs in Australia, 1990-1998 [Research] Peter McManus, Andrea Mant, Philip B Mitchell, William S Montgomery, John Marley and Merran E Auland Med J Aust 2000; 173: 458-461
COX-2 inhibitors [New Drugs, Old Drugs] Peter M Brooks and Richard O Day Med J Aust 2000; 173: 433-436
Anabolic-androgenic steroids: medical assessment of present, past and potential users [Medicine and the community] Anthony J O'Sullivan, Michael C Kennedy, John H Casey, Richard O Day, Brian Corrigan and Alex D Wodak Med J Aust 2000; 173: 323-327
An analgesic role for cannabinoids [Viewpoint] Christopher W Vaughan and Macdonald J Christie Med J Aust 2000; 173: 270-272
Ethical issues in placebo-controlled trials in Alzheimer's disease [Ethics] Robert D Goldney and Brian F Stoffell Med J Aust 2000; 173: 147-148
Migraine treatment and mistreatment: primum non nocere [Editorial] Peter J Goadsby Med J Aust 2000; 172: 412-413
Erectile dysfunction, sildenafil and cardiovascular risk [Clinical Update] K Kim Chew, Bronwyn G A Stuckey and Peter L Thompson Med J Aust 2000; 172: 279-283
Osteoporosis prevention and treatment [New Drugs, Old Drugs] Phillip N Sambrook and John A Eisman Med J Aust 2000; 172: 226-229
Use, misuse and abuse of androgens [Position Statement] Ann J Conway, David J Handelsman, Douglas W Lording, Bronwyn Stuckey, Jeffrey D Zajac, on behalf of the Endocrine Society of Australia Med J Aust 2000; 172: 220-224
The effectiveness of popular, non-prescription weight loss supplements [The Weight Debate] Garry Egger, David Cameron-Smith and Rosemary Stanton Med J Aust 1999; 171: 604-608
Childhood hepatotoxicity with paracetamol doses less than 150 mg/kg per day [Lessons from Practice] Jenny L Hynson & Mike South Med J Aust 1999; 171: 497
Accidental paracetamol overdosing and fulminant hepatic failure in children [Healthcare] Fiona K Miles, Ramananda Kamath, Stuart F A Dorney, Kevin J Gaskin and Edward V O'Loughlin Med J Aust 1999; 171: 472-475
Vancomycin and teicoplanin use in Victorian hospitals [Research] Marion B Robertson, Jonathan G A Dartnell and Tony M Korman, on behalf of the Victorian Drug Usage Evaluation Group Med J Aust 1999; 171: 127-131
Long hours are a financial reality [Matters Arising] Leslie G Olson Med J Aust 1998; 169: 341
Treat the cause, not the symptoms [Matters Arising] Michaela J Farrall Med J Aust 1998; 169: 340-341
Anabolic�androgenic steroids: medical assessment of <\n>present, past and potential users [Medicine and the community] Anthony J O�Sullivan, Michael C Kennedy, John H Casey, Richard O Day, Brian Corrigan and Alex D Wodak Med J Aust 1998; 169: 323-327
MaLAM, a medical lobby for appropriate marketing of pharmaceuticals [The power of one] Peter R Mansfield Med J Aust 1997; 167: 590-592
Antibiotic use in the Australian community, 1990-1995 Peter McManus, M Leigh Hammond, Susan D Whicker, John G Primrose, Andrea Mant, Steven R Fairall Med J Aust 1997; 167: 124-127
Antibiotic use or misuse? [Editorials] John Turnidge Med J Aust 1997; 167: 116-117
The use of oral opioids in patients with chronic non-cancer pain [Clinical practice] Paul J Graziotti and C Roger Goucke Med J Aust 1997; 167: 30-34
Australian trends in opioid prescribing for chronic non-cancer pain, 1986-1996 [Health care] James R Bell Med J Aust 1997; 167: 26-29
Movement disorders with selective serotonin reuptake inhibitors [ADRAC] ADRAC Med J Aust 1997; 166: 259
Benzodiazepine prescribing in a Sydney teaching hospital [Research] Jan B Howes, Jillian Ryan, Gregory Fairbrother,Kevin O'Neill, Laurence G Howes Med J Aust 1996; 165: 305
Benzodiazepine prescribing in a Sydney teaching hospital [Research] Jan B Howes, Jillian Ryan, Gregory Fairbrother,Kevin O'Neill, Laurence G Howes Med J Aust 1996; 165: 305
Oral retinoids and pregnancy Annabelle Chan, Marshall Hanna, Malcolm Abbott, Rosemary J Keane Med J Aust 1996; 165: 164
Drug-resistant Streptococcus pneumoniae: the beginning of the end for many antibiotics? [Research] Peter J Collignon, Jan M Bell and the AGAR Med J Aust 1996; 164: 64-67
We three kings and Christmas trees: pharmacotherapy from presents and diseases from decorations [Christmas Offerings] Stuart M Smith and B James McCallum Med J Aust ; 187 (11/12): 701-702.
Prevention of cardiovascular disease: an evidence-based clinical aid [MJA focus] Greg R Fulcher, Greg W Conner and John V Amerena, for the Practical Implementation Taskforce for the Prevention of Cardiovascular Disease MJA focus 21 July 2003: 1-14.
Correction [Correction] Lisa H Amir Med J Aust 2007; 186 (11): 606.
eMJA Mental Health Information: short course 6, Benzodiazepines in anxiety disorders [Short course] Trevor R Norman, Steven R Ellen, Graham D Burrows